A. H. Robins will consider Rorer’s merger offer.
Richmond, Va.-based Robins, the health-care company mired in bankruptcy proceedings brought on by its Dalkon Shield contraceptive, said its board had concluded that a merger offer by Rorer Group merited further consideration. At the request of the board, Rorer, a Fort Washington, Pa.-based drug company, agreed to extend by two days its deadline for a response from Robins. After failing in a previous attempt, Rorer announced a plan to merge with Robins through a stock swap worth a minimum of $725 million.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.